Translate Bio Revenue and Competitors

Claim your profile

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Translate Bio's estimated annual revenue is currently $238k per year.(i)
  • Translate Bio's estimated revenue per employee is $933

Employee Data

  • Translate Bio has 255 Employees.(i)
  • Translate Bio grew their employee count by 10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11830M5400%$2.7B$83B

Translate Bio is a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company's RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases caused by insufficient protein production, including rare diseases of the liver, lung and central nervous system (CNS).

keywords:N/A

N/A

Total Funding

255

Number of Employees

$238k

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Translate Bio News

2022-04-20 - mRNA Vaccines & Therapeutics Market Size, Outlook And ...

Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology.

2022-04-19 - mRNA Cancer Vaccines and Therapeutics Market Analysis ...

Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris,...

2021-08-06 - Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update

-- Entered into a definitive agreement under which Sanofi will acquire, subject to customary conditions to closing, all outstanding shares of Translate Bio with a goal of advancing deployment of mRNA technology across vaccines and therapeutics development -- -- Advanced mRNA infectious disease ...

2021-03-12 - Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels Expected to enroll 415 participants; interim results expected in Q3 2 ...

2021-02-18 - Translate Bio to Present at the SVB Leerink Virtual 10th Annual Global Healthcare Conference

LEXINGTON, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced that Ronald R ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.7M25621%N/A
#2
$59.6M258-1%N/A
#3
$28.2M266322%$202.2M
#4
$61.7M26715%N/A
#5
$15M268N/AN/A